Role of Finerenone in African American Veterans With Diabetic Kidney Disease (NCT07155694)
🩺 Plain-English Summary (8th-Grade Level)
Primary Objectives: To study podocyte specific injury markers (podocyte specific proteins, PSP) nephrin, podocalyxin and Wilms'Tumor (WT-1) protein in exosomes urine from African American Veterans with albuminuric stage 2 and 3 chronic diabetic kidney disease (DKD), using Empagliflozin or Finerenone or combination therapy. Secondary Objectives: (1). Correlate changes in exosome-based PSP with standardized biomarkers of kidney injury including urine albumin/creatinine ratio (ACR) and estimated GFR. (2) with systemic inflammatory markers (focusing on vascular and endothelial function) that are already established such as interleukins (IL1, IL6, IL-12), hs-CRP and (3) arterial stiffness measures and with (4) APOL1 mRNA expression levels in peripheral blood derived mononuclear cells (MNC).
Who can join: Review the eligibility criteria below.
Location: Washington DC Veterans Affairs Medical Center (688) — Washington D.C., District of Columbia
Age range: 20 Years to 90 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (1 Sites)
- Washington DC Veterans Affairs Medical Center (688) — Washington D.C., District of Columbia
📞 Contact the Study Coordinator
Phone: (202) 745-8000
Email: sabyasachi.sen@va.gov
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Diabetic Kidney Disease
- Decision Impact Trial of KidneyIntelX — Slingerlands, New York
- Prospective Decision Impact Trial of KidneyIntelX — Winston-Salem, North Carolina
- Pentoxifylline in Diabetic Kidney Disease — Phoenix, Arizona
- Prospective Decision Impact Clinical Utility Trial of KidneyIntelX — New York, New York
- Revealing Engagement Dynamics Among Diabetic Kidney Disease Patients — San Francisco, California
Explore by condition: All Diabetic Kidney Disease clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.